Key Summary: On September 16, 2024, Deep Track Capital (9.6%) announced plans to discuss the company's performance, governance (especially Board composition), and optimal use of excess cash with management and the board.Market Cap: $1.5 billion| Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
deep-track-capital-plans-discussions-on-dynavax-technologies-corporation-s-dvax-performance-and-goOn September 16, 2024, Deep Track Capital (9.6%) announced its intention to discuss with the management and board several issues, including the company's performance, business operations, strategic opportunities, governance (particularly Board composition), and the optimal use of excess cash. Source
Commentaires